Penserra Capital Management LLC Decreases Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Penserra Capital Management LLC cut its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 77.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,584 shares of the company's stock after selling 40,059 shares during the quarter. Penserra Capital Management LLC's holdings in Teva Pharmaceutical Industries were worth $178,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 197,885.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock worth $338,989,000 after acquiring an additional 22,044,407 shares during the last quarter. IFM Investors Pty Ltd raised its stake in shares of Teva Pharmaceutical Industries by 11.6% in the first quarter. IFM Investors Pty Ltd now owns 231,028 shares of the company's stock worth $3,551,000 after purchasing an additional 23,941 shares during the last quarter. D.A. Davidson & CO. lifted its holdings in shares of Teva Pharmaceutical Industries by 6.4% in the first quarter. D.A. Davidson & CO. now owns 94,586 shares of the company's stock valued at $1,454,000 after purchasing an additional 5,667 shares in the last quarter. WCM Investment Management LLC boosted its position in shares of Teva Pharmaceutical Industries by 57.0% during the first quarter. WCM Investment Management LLC now owns 213,157 shares of the company's stock valued at $3,214,000 after buying an additional 77,403 shares during the last quarter. Finally, DAVENPORT & Co LLC raised its position in Teva Pharmaceutical Industries by 23.4% in the 1st quarter. DAVENPORT & Co LLC now owns 470,828 shares of the company's stock valued at $7,237,000 after buying an additional 89,340 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on TEVA. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 target price for the company. Bank of America increased their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 target price for the company. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Finally, UBS Group decreased their target price on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $24.71.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock traded down $0.03 on Wednesday, hitting $16.02. 14,253,988 shares of the stock were exchanged, compared to its average volume of 10,316,462. The firm has a market capitalization of $18.37 billion, a PE ratio of -13.93, a P/E/G ratio of 0.97 and a beta of 0.60. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $22.80. The company has a current ratio of 1.03, a quick ratio of 0.74 and a debt-to-equity ratio of 2.59. The firm's 50 day moving average is $17.09 and its two-hundred day moving average is $17.06.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. The company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The firm's revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.48 EPS. Sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the sale, the executive vice president owned 9,989 shares of the company's stock, valued at $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.55% of the stock is owned by insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.